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Metabolic acidosis in maintenance dialysis patients: Clinical
considerations. Metabolic acidosis is a common consequence
of advanced chronic renal failure (CRF) and maintenance dial-
ysis (MD) therapies are not infrequently unable to completely
correct the base deficit. In MD patients, severe metabolic aci-
dosis is associated with an increased relative risk for death. The
chronic metabolic acidosis of the severity commonly encoun-
tered in patients with advanced CRF has two well-recognized
major systemic consequences. First, metabolic acidosis induces
net negative nitrogen and total body protein balance, which
improves upon bicarbonate supplementation. The data sug-
gest that metabolic acidosis is both catabolic and antianabolic.
Emerging data also indicate that metabolic acidosis may be
one of the triggers for chronic inflammation, which may in
turn promote protein catabolism among MD patients. In con-
trast to these findings, metabolic acidosis may be associated
with a decrease in hyperleptinemia associated with CRF. Sev-
eral studies have shown that correction of metabolic acidosis
among MD patients is associated with modest improvements
in the nutritional status. Second, metabolic acidosis has several
effects on bone, causing physicochemical dissolution of bone
and cell-mediated bone resorption (inhibition of osteoblast and
stimulation of osteoclast function). Metabolic acidosis is proba-
bly also associated with worsening of secondary hyperparathy-
roidism. Data on the effect of correction of metabolic acido-
sis on renal osteodystrophy, however, are limited. Preliminary
evidence suggest that metabolic acidosis may play a role in b2-
microglobulin accumulation, as well as the hypertriglyceridemia
seen in renal failure. Given the body of evidence pointing to the
several systemic consequences of metabolic acidosis, a more
aggressive approach to the correction of metabolic acidosis is
proposed.
Metabolic acidosis is a common accompaniment of
chronic renal failure (CRF) and it results from an inability
to excrete nonvolatile acid in the face of reduced renal
bicarbonate synthesis. The severity of metabolic acido-
sis can vary widely among uremic patients with a similar
degree of renal dysfunction [1, 2]; at least two studies
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suggest that for a given level of renal function, diabetic
individuals may have a less severe degree of metabolic
acidosis [3, 4]. One of the goals of dialysis therapy is to
correct the metabolic abnormalities of uremia, includ-
ing metabolic acidosis. Dialysis therapies, as practiced
today, are unable to completely correct metabolic aci-
dosis in a substantial proportion of patients undergoing
maintenance hemodialysis (MHD). Moreover, the serum
bicarbonate levels in patients undergoing MHD follow a
“saw-tooth pattern,” with the lowest bicarbonate levels in
the immediate predialysis period. Treatment with chronic
peritoneal dialysis (CPD), on the other hand, appears
to maintain stable serum bicarbonate within the normal
range in the majority of patients, without the fluctuations
seen among patients undergoing MHD [5]. Even though
CPD therapy is successful in normalizing the serum CO2
levels in almost 90% of patients, the anion gap remains
wide in over 95% of patients [5]. The magnitude of anion
gap in CPD patients is associated with higher serum urea
nitrogen and phosphorus concentration, suggesting an in-
adequate metabolic control by the dialysis prescription.
The relevance of these findings is addressed below.
Increasing evidence points to a role, at least in part, for
metabolic acidosis in the genesis, of several uremic mani-
festations (Table 1). Moreover, in a retrospective analysis
of a large cohort of patients, Lowrie et al [6] demonstrate
that total serum CO2 was associated with a J-shaped
risk for death: increasing risk for death was observed
when the total serum level was less than 17.5 mmol/
L or greater than 25 mmol/L. The magnitude of the an-
ion gap has sometimes been used as a surrogate for the
severity of metabolic acidosis. The available data suggest
that this assumption may be erroneous at least among
patients undergoing CPD—the vast majority of patients
with a widened anion gap have normal serum bicarbonate
concentrations [5]. When the data are adjusted for case-
mix, a high anion gap is associated with lower odds for
death in MHD patients [7]. However, when the data are
adjusted for serum albumin and creatinine levels along
with case-mix, an increase in anion gap is associated with
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Table 1. Adverse systemic consequences of metabolic acidosis
Nutritional consequences
Catabolic effects—Increased proteolysis
Antianabolic effects—Decreased protein synthesis
Insulin resistance
Systemic inflammation
Decreased serum leptin levels
Bone disease
Direct effects
Physicochemical dissolution of bone
Decreased function of osteoblast
Increased function of osteoclast
Indirect effects
Increased release of parathyroid hormone
Increased number of parathyroid hormone receptors
Increased binding of parathyroid hormone to its receptor
Reduced activity of 1-a hydroxylase
Other systemic effects
Increased generation and release of b2-microglobulin
Hypertriglyceridemia
a progressive increase in the risk for death [7]. The direct
association of a widened anion gap with the risk for death
is consistent with the thesis that a persistent increase in
anion gap may reflect inadequate dialysis with respect to
metabolic control. It is not clear, however, if an increase
in dialysis dose can normalize the anion gap, or what the
effect of the normalization of the anion gap would have
on morbidity and mortality.
In this review, we present a brief overview of some of
the systemic consequences of metabolic acidosis in indi-
viduals with advanced CRF or undergoing MHD. There
are many other consequences of metabolic acidosis, espe-
cially if very severe, (e.g., malaise, weakness, hypotension,
resistance to catecholamines). However, we shall limit
the discussion herein to metabolic acidosis that results
from CRF and consequences from the range of severity
that usually occurs in nondialyzed CRF and MHD pa-
tients. Even though it is assumed that the systemic conse-
quences arise from an increase in the total hydrogen ion
concentration in the blood (acidemia), some of the data
presented here are based only upon a measurement of
plasma bicarbonate or serum total CO2.
GENERAL CONSIDERATIONS
There are two major considerations to take into ac-
count while assessing the acid-base status of patients un-
dergoing MHD: factors related to the measurement of
total serum CO2 levels; and the effect of changing pat-
terns of use of phosphate binders on the acid-base status.
Factors related to measurement of serum total CO2 levels
Close attention needs to be paid to two variables with
respect to measurement of total CO2 levels. First, un-
derfilling of sample tubes should be avoided because
evanescence of carbon dioxide may result in falsely low
measurements [8]. Second, shipping blood samples by
overnight airfreight to laboratories several hundred miles
away is a standard practice in a large number of dial-
ysis units in the United States. This practice has been
shown to be associated with a frequent occurrence of
spurious metabolic acidosis; the mean total CO2 content
of blood samples thus shipped is 5 mEq/L lower than
samples that undergo more immediate processing [9, 10].
This decrease in total CO2 content cannot be accounted
for by an increase in lactate content or by the interval be-
tween sample collection and processing. It is likely that
changes in atmospheric pressure in the pressurized air-
liner cabin or in a cargo hold lead to the escape of CO2
from the tube [11]. Indeed, if the sample is stored either
at room temperature or refrigerated for 24 hours without
air transport, the change in total CO2 is only 1 mEql/L
[9, 12]. Thus, in MD patients, caution needs to be exer-
cised in interpreting serum chemistry measurements that
indicate metabolic acidosis.
The effect of changing patterns of use of phosphate
binders on the acid-base status
Until recently, almost all MHD patients were treated
with calcium-based phosphate binders, calcium acetate
and calcium carbonate. Both of these calcium salts are
alkalies and these medications have a salutary effect on
metabolic acidosis. However, one recent study suggests
that a high dose of calcium-based phosphate binders is
associated with the presence of coronary artery calcifica-
tion in MHD patients [13]. In a randomized control trial
involving 200 MHD patients, the median percent change
in coronary artery (25% vs. 6%) and aortic (28% vs. 5%)
calcium scores was significantly greater with calcium-
based phosphate binders, compared with sevalemer
hydrochloride [14]. These findings have engendered an
increasing use of sevalemer hydrochloride as a phosphate
binder. However, sevalemer hydrochloride acts like an
ion-exchange resin in the gastrointestinal tract—it re-
leases one mole of chloride for every mole of phosphorus
that it binds. Because 17% of sevalemer hydrochloride is
chloride by weight, treatment with four 800 mg tablets of
sevalemer hydrochloride three times per day with meals
provides 46 mEq of chloride load per day. The chloride
thus released is buffered by bicarbonate, leading to a non-
gap metabolic acidosis. These considerations suggest that
a change from widespread use of alkalies for phosphate
binding to the use of an agent that fosters chloride loading
may lead to a greater prevalence of persistent metabolic
acidosis among MHD patients [15–17].
METABOLIC ACIDOSIS AND NUTRITION
In 1931, Lyon et al [18] first suggested that there may be
a link between metabolic acidosis and nutritional status
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Metabolic acidosis
Mechanisms yet to be elucidated
Insulin resistance
Increased activity of
branched chain ketoacid
dehydrogenase
Increased activity of
ATP-dependent
ubiquitin-proteasome
system
Increased muscle protein
breakdown
Inflammation
Reduced
serum leptin
Decreased muscle protein synthesis
Decreased albumin synthesis
Protein energy
malnutrition
Fig. 1. The mechanisms by which metabolic acidosis may induce protein-energy malnutrition. Of the various pathways, the stimulation of the
ATP-dependent ubiquitin-proteasome system by metabolic acidosis is the most well defined. Dotted lines indicate that the data supporting the role
of these pathways are less well documented at this time.
of patients with CRF. A large body of literature has subse-
quently accumulated that suggests that metabolic acido-
sis may play an important role in the pathogenesis of the
nutritional abnormalities associated with uremia. There
are five potential mechanisms by which metabolic acido-
sis contributes to these nutritional abnormalities. One of
these is well-researched and understood (increased pro-
tein catabolism); more is being learned about two others
(decreased protein synthesis and increased insulin resis-
tance); and research has only begun to explore the role of
two others (inflammation and reduction in serum leptin
levels) (Fig. 1).
Increased protein breakdown (catabolic effects
of metabolic acidosis)
Evidence for proteolysis. Evidence derived from ani-
mal and human studies suggests that acidosis, including
that associated with CRF, is associated with proteolysis,
and correction of this acidosis leads to a decrease in pro-
tein breakdown.
Acute metabolic acidosis in dogs leads to increased
total-body leucine oxidation, which is reduced with
metabolic alkalosis [19]. Studies in rats with normal renal
function demonstrate that ammonium chloride–induced
metabolic acidosis leads to an increase in skeletal mus-
cle protein degradation and amino acid oxidation [20–
23]. Increased muscle protein degradation has also been
reported in rats with experimental renal failure; this in-
creased protein breakdown was ameliorated by adding
sodium bicarbonate to their diet [24].
In both healthy humans and individuals with CRF,
metabolic acidosis may also engender negative N bal-
ance [25–27]. A large number of investigations in humans
with various stages of renal failure have demonstrated
that metabolic acidosis promotes proteolysis (Table 2)
[28–35].
Pathophysiologic mechanisms for the increased proteol-
ysis associated with metabolic acidosis. Two key mech-
anisms have been identified that mediate the catabolic
effects of metabolic acidosis.
Increased activity of branched-chain ketoacid dehydro-
genase (BCKAD). Studies in intact rats and in isolated
muscles demonstrate that acidosis stimulates the break-
down of branched-chain amino acids (BCAA) [36].
This catabolic response in muscle is associated with in-
creased mRNAs and activity of the rate-limiting enzyme
branched-chain ketoacid dehydrogenase (BCKAD)
[21, 37]. The plasma and muscle levels of BCAA are
significantly lower in animal models of metabolic acido-
sis, as well as in humans undergoing MD therapy [21,
38, 39]. Moreover, in MHD patients, the free valine
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Table 2. Summary of controlled metabolic studies in humans that suggest that metabolic acidosis promotes catabolism
No. of Stage of renal Baseline Final Biologic phenomena Results of correction of
Author subjects failure pH pH studied metabolic acidosis
Papadoynnakis [27] 6 Nondialyzed a a N and K balance Both N and K balance improved
Williams [28] 6 Nondialyzed 7.28 7.35 3-methyl histidine:creatinine ratio In patients on low protein diets,
increased urinary excretion in the
presence of metabolic acidosis,
reduced with NaHCO3
supplementation
Reaich [29] 9 Nondialyzed 7.31 7.38 L[1-13C]leucine kinetics Reduced protein degradation and
synthesis and leucine oxidation
Garibotto [30] 9 Nondialyzed a a 3H-phenylalanine kinetics Net phenylalanine release inversely
related to degree of acidosis
Graham [31] 7 CPD 7.39 7.41 L[1-13C]leucine kinetics Reduced whole body protein
degradation and synthesis; no
effect on leucine oxidation
Graham [32] 6 MHD 7.36 7.40 L[1-13C]leucine kinetics Reduced whole body protein
degradation and synthesis; no
effect on leucine oxidation
Lofberg [33] 9 MHD a a Intracellular branched amino acids Increased intracellular
concentrations of branched-chain
amino acids
Lim [34] 8 Nondialyzed 7.29 7.39 L[1-13C]leucine kinetics Significant increase in leucine
oxidation, insignificant increase in
protein degradation and synthesis
Boirie [35] 10 Nondialyzed a a L[1-13C]leucine kinetics Acidotic children had higher rates
of protein degradation
CPD, chronic peritoneal dialysis; MHD, maintenance hemodialysis.
aData not available.
concentrations in the muscle correlate with both the
pre- and postdialysis plasma bicarbonate levels [38].
Correction of metabolic acidosis in MHD patients is
associated with an increase in plasma BCAA (leucine,
isoleucine, and valine) levels [40]. Thus, it is likely that
in humans, the metabolic acidosis associated with renal
failure engenders an increased activity of BCKAD,
which in turn leads to increased catabolism of BCAA.
Increased activity of the ATP-dependent ubiquitin-
proteasome pathway. There are several lines of evidence
that establish the role of this pathway in mediating the
catabolic effects of metabolic acidosis in CRF. First,
metabolic acidosis in rats with CRF is associated with an
increase in the muscle content of the mRNAs encoding
the ATP-dependent ubiquitin, as well as the subunits of
the proteasome [41]. Feeding chow mixed with sodium
bicarbonate reversed these responses. This increase in
mRNA is secondary to increased gene transcription [41,
42]. Second, when isolated rat muscles are either depleted
of ATP or exposed to an inhibitor of the proteasome in
the presence of metabolic acidosis, the increase in protein
degradation is abolished [20, 23, 41]. Third, incubating
skeletal muscle from CRF rats with metabolic acidosis
with an inhibitor of the proteasome suppresses proteoly-
sis [41]. Finally, in a recent study involving CPD patients,
Pickering et al [43] demonstrated that an increase
in serum total CO2 was associated with a significant
reduction in the muscle content of ubiquitin mRNA. In
contrast, there was no demonstrable increase in the
muscle ubiquitin mRNA levels in eight MHD patients
with only mild metabolic acidosis as compared to
healthy control patients [44]. These data suggest that the
ubiquitin-proteasome pathway plays an important role
in protein catabolism associated with metabolic acidosis.
Triggers for acidosis-induced enhancement of proteoly-
sis in skeletal muscle. Despite the impressive progress
in understanding the molecular mechanisms involved
in proteolysis in the setting of metabolic acidosis, the
triggers that activate these molecular mechanisms are
poorly understood. It appears unlikely to be the pH it-
self, because metabolic acidosis in CRF does not cause
a sustained alteration in the intracellular pH of muscle
[45]. Several hormonal triggers have been proposed and
studied.
Ammonium chloride–induced metabolic acidosis in
adrenalectomized rats does not induce protein degrada-
tion, an increase in the gene expression of BCKAD or
its activity, or an elevation in any of the mRNAs of the
ubiquitin-proteasome system in muscle [20, 42, 46]. More-
over, the urinary excretion of corticosterone in rats with
acidotic experimental renal failure is significantly higher
than of pair-fed control rats [21]. These data suggest that
glucocorticoids may play a facilitative role in inducing
the catabolic pathways in the setting of metabolic acido-
sis. Indeed, a glucocorticoid responsive element in the
promoter region of BCKAD has recently been discov-
ered [47]. Increased urinary cortisol excretion has also
been reported in one experimental study of ammonium
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chloride–induced metabolic acidosis of eight days’ dura-
tion [48]. The role of glucocorticoids, however, in trig-
gering the catabolic pathways in metabolic acidosis with
CRF is less clear. Garibotto et al [30] found that mus-
cle protein degradation correlated directly with plasma
levels of cortisol and negatively with serum bicarbonate,
suggesting that both acidosis and glucocorticoids may be
needed to stimulate muscle protein degradation. Other
investigators have been unable to demonstrate elevated
cortisol concentrations in the setting of chronic metabolic
acidosis [26, 49–51]. These observations, however, do not
exclude the possibility that corticosteroids may need to be
present for acidemia to stimulate skeletal muscle protein
degradation.
Insulin resistance may play a role in the activation of
the ubiquitin-proteasome system. The high rate of protein
degradation in rats with acute onset of diabetic mellitus
is not reduced by correction of the diabetic ketoacido-
sis, but administration of insulin for 12 hours eliminated
the excess proteolysis and higher ubiquitin mRNAs [52].
Moreover, insulin-stimulated phosphorylation of insulin-
receptor substrate-1 phosphatidylinositol 3 kinase acti-
vity is significantly reduced in the muscle of rats with
renal failure [53]. It is possible, then, that suppressed
phosphatidylinositol 3 kinase activity may lead to acti-
vation of the ubiquitin-proteasome pathway and muscle
protein degradation [53].
Reduced tissue levels of or increased resistance to
other anabolic hormones may also play a role in stim-
ulating the catabolic pathways (see below).
Decreased muscle protein synthesis (antianabolic
effects of metabolic acidosis)
Cell culture studies using BC3H1 myocytes have shown
a significant reduction in protein synthesis in an acidic
medium [abstract; Ding et al, J Am Soc Nephrol 9:607A,
1998] [54]. Increases in the pH of the medium (up to 7.70),
even above normal physiologic pH, were associated with
progressively higher rates of protein synthesis [abstract;
Ding et al, J Am Soc Nephrol, 9:607A, 1998]. Similarly,
protein synthesis is significantly reduced in L6 muscle
cells cultured in an acidic medium [55]. Finally, acidic cul-
ture medium significantly reduces the albumin and trans-
ferrin concentrations in the supernatant of HepG2 cell
cultures [56].
Rather analogous results have been observed in some
but not all studies of metabolic acidosis in humans. Acute
ammonium chloride–induced metabolic acidosis in nor-
mal individuals is associated with a significant reduc-
tion in the fractional synthetic rate of muscle protein;
the fractional, as well as the absolute, rate of albumin
synthesis remained unchanged [50]. On the other hand,
chronic ammonium chloride–induced metabolic acido-
sis is reported to significantly reduce the fractional syn-
thetic rate of albumin [25]. The applicability of these
findings to metabolic acidosis in CRF is uncertain. Some
studies in MHD patients, using L-(13C)-leucine kinetics,
demonstrate an increased total body protein synthesis
with metabolic acidosis, which decreases upon correc-
tion of acidosis [29, 31, 32]. In these studies, however, the
presence of metabolic acidosis was also associated with a
significantly greater increase in the rate of protein degra-
dation, resulting in a net negative protein balance [29, 31,
32]. Thus, additional data are needed to determine the ef-
fects on protein synthesis of metabolic acidosis associated
with CRF in humans.
Alterations in one or more of three hormonal sys-
tems may be responsible for the antianabolic effects of
ammonium chloride–induced metabolic acidosis. First,
metabolic acidosis may reduce the release of growth
hormone; experimental data also suggest that metabolic
acidosis may lead to peripheral resistance to growth hor-
mone [57, 58]. Second, animal and human studies show
that metabolic acidosis is associated with a significant re-
duction in the plasma levels of insulin-like growth fac-
tor (IGF) and the hepatic content of IGF-I mRNA [25,
58–60]. Third, thyroid hormones exert anabolic effects,
and decreased thyroid function induced by metabolic aci-
dosis might contribute to reduced synthesis of muscle
protein. In acute metabolic acidosis, there is a slight but
significant increase in thyroid-stimulating hormone levels
without any change in free triiodothyronine levels [50].
In chronic metabolic acidosis, the same investigators re-
ported a significant reduction in triiodothyronine levels
without any change in thyroid-stimulating hormone lev-
els [25]. Brungger et al [60] have reported similar results
in an experimental study of chronic acidosis in humans.
The relative contributions of these hormonal systems to
the altered anabolic and catabolic pathways induced by
metabolic acidosis, however, needs to be defined more
precisely.
Insulin resistance
Insulin resistance is a known complication of CRF [61].
Evidence suggests that this insulin resistance may in part
be secondary to metabolic acidosis [62]. In the presence of
acidosis, insulin binding in rat adipocytes is reduced by up
to 30%. Hyperglycemic and euglycemic clamp studies in
the presence of ammonium chloride–induced metabolic
acidosis revealed impaired glucose metabolism due to re-
duced tissue sensitivity to insulin [62]. Indeed, correction
of metabolic acidosis in nondialyzed patients with CRF
enhances insulin-stimulated glucose uptake.
Metabolic acidosis and inflammation: Is there a link?
Incubation of peritoneal macrophages in an acidic cell
culture medium results in an increased production of
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Table 3. Epidemiologic cross-sectional studies evaluating relationship between nutritional status and metabolic acidosis in MHD patients
No. of Dialysis Key findings suggesting that metabolic acidosis may not be associated
Author [ref.] subjects type with impaired nutritional status
Kang [73] 106 CPD Patients with serum total CO2 <22, compared to with total CO2 ≥26, had higher relative body weight,
SUN, serum albumin, nPNA, and ultrafiltration volume
Uribarri [74] 23 MHD Patients with serum total CO2 ≤21 vs. total CO2 ≥25 had higher serum creatinine and SUN; significant
inverse relationship between total CO2 and nPNA
Dumler [75] 50 CPD No difference in body cell mass or fat-free, edema-free mass between acidotic and nonacidotic groups;
BMI higher in acidotic group
Ge [76] 75 MHD Lower relative body weight, triceps skin-fold thickness, midarm muscle circumference, serum albumin,
transferrin, and fibronectin levels in patients with severe metabolic acidosis
Movilli [77] 81 MHD Direct association between serum bicarbonate and albumin levels
Dumler [78] 124 Higher serum albumin, creatinine, and nPNA2 in acidotic group; no difference in body cell mass, fat-free
edema-free mass or mid-arm circumference between acidotic and non-acidotic group
Uribarri [79] 995 MHD Serum total CO2 inversely associated with DPI4, nPNA2 and predialysis serum potassium, phosphorus,
creatinine, SUN1; no relationship with BMI3 or skinfold thickness
Gao [80] 50 MHD Serum total CO2 inversely related to SUN, serum phosphorus, and uric acid
Leavey [81] 3891 MHD Significant inverse relationship with serum albumin
Chauveau [82] 7123 MHD Plasma HCO3 inversely associated with nPNA2, serum albumin, prealbumin, BMI, and fat-free,
edema-free mass
Kung [83] 43 CPD Malnourished subjects determined by subjective global assessment, had higher serum total CO2 than
well-nourished subjects
Lin [64] 120 MHD Higher BMI, triceps skin-fold thickness, DPI, nPNA, serum creatinine, and potassium in acidemic
patients
Abbreviations are: SUN, serum urea nitrogen; nPNA, normalized protein equivalent of nitrogen appearance; BMI, body mass index; DPI, dietary protein intake;
CPD, chronic peritoneal dialysis; MHD, maintenance hemodialysis.
tumor necrosis factor a (TNFa), suggesting a possible
link between metabolic acidosis and the inflammatory
cascade [63]. Two recent studies have investigated the link
between metabolic acidosis and inflammation. In a cross-
sectional study of MHD patients, there was no significant
difference in the serum levels of C-reactive protein and
interleukin-6 in three groups of patients, divided on the
basis of their serum total CO2 levels (mean total CO2 in
the three groups, 19.2, 24.4, and 27.5 mmol/L) [64]. On the
other hand, the correction of metabolic acidosis in eight
CPD patients was associated with a significant decrease
in TNFa levels [43]. Future studies need to define the
relationship between metabolic acidosis associated with
CRF and inflammation.
Leptin and metabolic acidosis
Leptin, a product of the ob gene, has been studied
as a potential mediator of protein-energy malnutrition.
Serum leptin is elevated in CRF. Even though the precise
role of leptin in human renal disease remains to be de-
fined, three longitudinal studies have demonstrated that
individuals with high serum leptin levels are more likely
to lose weight [65–67]. Several recent studies have ex-
plored the interaction between metabolic acidosis and
hyperleptinemia, two frequent consequences of CRF.
Adipocytes exposed to a low pH (pH 7.1) in a culture
medium exhibit decreased leptin secretion [68]. In rats
with renal failure treated with sodium bicarbonate, the
serum leptin is significantly lower than in those not sup-
plemented with bicarbonate [68]. Furthermore, plasma
leptin concentrations are lower in patients with diabetic
ketoacidosis than in healthy subjects, and the leptin levels
increase after initiation of insulin therapy [69, 70]. How-
ever, diabetic ketoacidosis is associated with insulinope-
nia, ketonemia, and increased sympathetic nervous ac-
tivity and these factors may independently affect serum
leptin levels. Among nondialyzed individuals with CRF,
correction of metabolic acidosis is associated with an in-
crease in serum leptin levels [71]. In a cross-sectional
study of 94 MHD patients, Kokot et al [72] were unable to
demonstrate any correlation between blood hydrogen ion
concentration and serum leptin levels; there was a trend,
not statistically significant, toward a progressively lower
median leptin concentration with progressively higher
blood hydrogen concentration.
Because elevated serum leptin levels lead to weight
loss, a decrease in serum levels could adaptively amelio-
rate the catabolic effects of metabolic acidosis. To the
authors’ knowledge, there are no published data regard-
ing the interaction of metabolic acidosis with serum lep-
tin levels and the relative contribution of each on the
nutritional status of MHD patients.
Cross-sectional and interventional studies concerning
potential adverse effects of metabolic acidosis
on the nutritional status of MHD patients
Notwithstanding the preponderance of metabolic stud-
ies that indicate an adverse catabolic response to
metabolic acidosis, the vast majority of cross-sectional
studies demonstrate an inverse relationship between
metabolic acidosis and the nutritional status of MHD
patients (Table 3) [64, 73–83]. The explanation for this
phenomenon may lie in the likelihood that healthy
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Table 4. Interventional studies that have evaluated the nutritional response to correction of metabolic acidosis in MHD patients
No. of Duration of Randomized Baseline vs. final pH Final pH (control Key findings (beneficial
Author [ref.] subjects treatment control trial in study group vs. study group) effects are italicized)
MHD patients
Seyffart [84] 21 12–19 months No a a Significant increase in dry body weight in
11 of 21 patients
Roberts [85] 8 Four weeks No 7.32 vs. 7.36 No change in nPNA or DPI
Kooman [40] 12 Six months No a a No change in body composition, serum
proteins or dietary intake; increased
plasma branched-chain amino acid
levels
Williams [86] 46 Six months Yes (double
crossover)
7.38 vs. 7.43 a Increased triceps skin-fold thickness; no
change in serum albumin, nPNA, or
midarm muscle circumference
Brady [87] 36 Four months Yes a a No change in serum albumin or total
lymphocyte count
Movilli [88] 12 Three months No 7.34 vs. 7.40 a Increase in serum albumin, decrease in
nPNA
Lin, ’02 [64] 17 Six months No 7.34 vs. 7.41 a No change in any nutritional parameters
Verove [89] 18 Six months No a a Significant increase in serum albumin and
prealbumin levels; decrease in nPNA;
no change in DPI
CPD patients
Stein [90] 200 One year Yes a 7.40 vs. 7.44 Greater gain in body weight and midarm
muscle circumference
nPNA, normalized protein equivalent of nitrogen appearance; DPI, dietary protein intake.
aData not available or applicable.
people tend to have greater appetite and, hence, ingest
more protein. Healthier people are not likely to show
manifestations of protein-energy malnutrition. More-
over, a higher protein (and consequently higher energy)
diet may reduce the risk of protein-energy malnutrition.
Finally, a higher intake of dietary protein is associated
with a higher dietary acid load and, thus, a lower serum
total CO2 level. This, in turn, appears to confound the
association of low serum total CO2 levels with increased
protein catabolism. However, cross-sectional studies only
demonstrate associations, and care must be exercised be-
fore concluding that mild to moderate metabolic acido-
sis has no deleterious effect on the nutritional status of
MD patients. In contrast to these findings, in a cross-
sectional evaluation of 81 MHD patients, Movilli et al
[77] demonstrated a direct association between serum
bicarbonate and serum albumin. Similarly, Ge et al [76]
demonstrated that MHD patients with severe metabolic
acidosis had significantly lower relative body weight, tri-
ceps skin-fold thickness, midarm muscle circumference,
serum albumin, transferrin, and fibronectin levels when
compared to those with higher serum bicarbonate lev-
els. It is also possible that the protein catabolic effects
associated with metabolic acidosis may be rather tran-
sient because in most studies, the metabolic acidosis or
bicarbonate therapy was maintained for a relatively short
period of time.
Several investigators have prospectively evaluated the
effect of correcting metabolic acidosis on the nutritional
status of MD patients [40, 64, 84–90]. As is shown in
Table 4, the beneficial results were inconsistent and usu-
ally limited. There are two major limitations of these stud-
ies. First, the sample size in most of these studies was small
and, thus, underpowered to detect an improvement in
nutritional status. Indeed, the largest study reported to
date successfully demonstrated an improvement in body
weight and triceps skin-fold thickness upon correction of
metabolic acidosis [90]. Second, a significant number of
the individuals studied had either normal or only mildly
impaired nutritional status.
These considerations suggest that there is a need for
a large, controlled trial to evaluate the effects of correc-
tion of metabolic acidosis on the nutritional status of MD
patients.
METABOLIC ACIDOSIS AND BONE DISEASE
Early studies in humans with advanced CRF not
treated by MHD indicate that a marked reduction in net
acid excretion leads to daily net positive proton balance
[91, 92]. It has been suggested that the cost of maintain-
ing a stable serum total CO2 in the face of uncorrected
metabolic acidosis was a constant dissolution of bone
buffers (Fig. 2) [92, 93]. Studies by Uribarri et al [94] have,
however, demonstrated that early studies had method-
ologic errors that may have led to an overestimation of
endogenous acid production and/or underestimation of
net acid excretion. Thus, the magnitude of daily positive
proton balance in the presence of renal failure may have
been significantly overestimated.
Direct effects of acidosis on bone
In vitro studies have shown that metabolic acidosis is
associated with net calcium efflux from bone [95]. The
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Fig. 2. The various mechanisms by which metabolic acidosis may contribute to bone disease. Dotted lines indicate that the data supporting the
role of these pathways are less well documented at this time.
net calcium efflux is a result of direct physicochemical
dissolution of bone as well as cell-mediated bone resorp-
tion (inhibition of osteoblast and stimulation of osteoclast
function) [96–98]. Metabolic acidosis also stimulates os-
teoblasts to release prostaglandins, which in turn in-
hibits osteoblastic activity and stimulates osteoclastic
function [99–102]. Glucocorticoids inhibit the production
of prostaglandins by osteoblasts, and this in turn inhibits
the acidosis-induced bone resorption [103]. Furthermore,
since acid loading in normal animals and humans is asso-
ciated with hypercalciuria and phosphaturia, it has been
suggested that bone is a major site for the extracellu-
lar buffering of the retained acid [92, 97, 104–109]. Con-
sistent with this thesis is the observation that metabolic
acidosis is associated with a decrease in the content of
bone bicarbonate [110, 111]. Finally, bicarbonate supple-
mentation in postmenopausal women with normal renal
function is associated with decreases in urinary cal-
cium, phosphorus, and hydroxyproline, and increased os-
teocalcin levels, suggesting an overall beneficial effect
[112]. These observations also suggest that uncorrected
metabolic acidosis has adverse consequences on bone
anatomy and physiology.
Since acidosis in CRF is not associated with hypercalci-
uria, the relevance of these findings to human renal failure
has been questioned [113, 114]. Several lines of evidence
support a role for metabolic acidosis in the pathogene-
sis of bone disease in CRF; most of these studies were
published 20 to 35 years ago. First, advanced uremia in
humans is associated with a decrease in the content of
calcium carbonate in bone [115–117]. Second, metabolic
acidosis in CRF is associated with a net negative cal-
cium balance; when metabolic acidosis is corrected, the
calcium balance becomes less negative [92, 106]. It is
not known if such acute effects of metabolic acidosis
on calcium balance will persist chronically. Third, stud-
ies in nondialyzed individuals with CRF showed that se-
vere metabolic acidosis is associated with impaired bone
mineralization and an increased incidence of osteoma-
lacia [106, 118–120]. Indeed, Mora Palma et al [119] re-
ported that over one third of 327 nondialyzed patients
with renal failure who had undergone a bone biopsy had
evidence for osteomalacia; the individuals with osteo-
malacia were characterized by a more severe degree of
metabolic acidosis. Fourth, Cochran et al [106] demon-
strated a significant increase in bone mineralization rate
after the correction of metabolic acidosis in nondialyzed
individuals with CRF. Fifth, cross-sectional analyses of
individuals with a renal transplant demonstrate a signif-
icant direct relationship between bone mineral density
and plasma bicarbonate levels, using Cox multivariate
proportional hazard analysis [121]. Finally, acute correc-
tion of metabolic acidosis in nondialyzed CRF patients
is associated with increased plasma levels of osteocal-
cin and procollagen type 1 carboxyterminal propeptide,
suggesting an improvement in osteoblast function [122,
123]. Notwithstanding these findings, the precise con-
tribution of metabolic acidosis to the bone disease in
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nondialyzed individuals with CRF and MHD patients
remains uncertain.
Indirect effects: Acidosis and parathyroid hormone
Among individuals with normal renal function,
metabolic acidosis is associated with three physiologic
changes with varying effects on serum parathyroid hor-
mone (PTH) concentrations: there is an increase in serum
ionized calcium, hypercalciuria, and a reduced sensitiv-
ity of the PTH secretion in response to ionized calcium
[124–126]. With decreased sensitivity of the parathyroid
gland to calcium, the rise in ionized calcium may not be
sufficient to maintain the normal serum PTH levels. In-
deed, early investigations among individuals with normal
renal function suggest that the hypercalciuria associated
with metabolic acidosis leads to an increase in serum PTH
levels [125]. In nondialyzed individuals with CRF, there is
an inverse relationship between plasma bicarbonate and
serum PTH levels that is consistent with these observa-
tions [127]. This relationship may have been secondary to
the bicarbonaturia that is associated with elevated serum
PTH levels. However, the rapid correction of metabolic
acidosis in this latter group of patients is associated with
a decrease in serum PTH levels, arguing against a role for
bicarbonaturia [123].
The available evidence, although not conclusive, sug-
gests that metabolic acidosis is also associated with an
increase in serum PTH levels in MHD patients. In a ran-
domized controlled study of 21 patients, Lefebvre et al
[128] demonstrated that in MHD patients treated with
a higher dialysate bicarbonate, there was no significant
increase in serum PTH levels over time; however, in the
group of patients treated with standard dialysate bicar-
bonate and persistent metabolic acidosis, serum PTH lev-
els increased significantly. In addition, some (although
not all) investigators report a decrease in serum PTH
levels after correction of metabolic acidosis in MHD pa-
tients [64, 86, 129, 130].
Early studies reported that PTH causes a greater in-
crease in serum calcium in the presence of metabolic
acidosis [131]. Moreover, using isolated perfused canine
tibia, Martin et al [132] demonstrated that metabolic aci-
dosis enhances the generation of cyclic AMP in response
to PTH, an event which may promote bone resorption.
Two recent studies have shed greater light on this is-
sue. First, using neonatal mouse calvariae, Bushinsky and
Nilsson [133] have demonstrated that in the presence of
metabolic acidosis, PTH stimulates greater net efflux of
calcium, inhibition of osteoblast activity, and enhance-
ment of osteoclast function. Second, using UMR 106-01
osteoblast-like cells, Disthabanchong et al [134] recently
demonstrated that acid culture medium increases PTH
receptor mRNA, raises the binding of PTH to its receptor,
and enhances the PTH-stimulated generation of cyclic
AMP. These findings suggest that metabolic acidosis may
enhance the peripheral actions of PTH on bone.
Thus, although the evidence cannot be considered
conclusive, the available data suggest that metabolic
acidosis may lead to a worsening of secondary hyper-
parathyroidism.
Indirect effects: Acidosis and vitamin D
Metabolic acidosis reduces activity of 1a-hydroxylase
in the renal tubules of rats [135]. The data regarding the
effects of metabolic acidosis on serum levels of 1,25 di-
hydroxycholecalciferol are difficult to interpret because
they are confounded by the effects of acidosis on levels
of serum phosphorus and PTH. Thus, studies have in-
dicated that metabolic acidosis may be associated with
increased, unchanged, or decreased levels of serum 1,25
dihydroxycholecalciferol levels [108, 129, 136–139].
Does correction of metabolic acidosis increase
the risk for metastatic calcification?
It has been proposed that postdialysis alkalosis may
increase the risk for metastatic calcification. However,
Harris et al [140] treated nine MHD patients with a higher
dialysate bicarbonate concentration of 40 mmol/L for
four weeks. They observed that the risk of metastatic cal-
cification between standard and high dialysis bicarbonate,
as determined by plasma inorganic phosphate, estimated
plasma tribasic inorganic phosphate (the phosphate com-
ponent of hydroxyapatite), and magnitude of postdial-
ysis phosphate rebound, was not significantly different
between the two groups with different dialysate bicar-
bonate concentrations. This evidence, however, is indi-
rect and the question needs further evaluation.
OTHER SYSTEMIC CONSEQUENCES
OF ACIDOSIS
b2-microglobulin levels
Several lines of evidence suggest that metabolic aci-
dosis may increase the serum levels of b2-microglobulin.
First, cell culture studies suggest that metabolic acidosis
may enhance cellular b2-microglobulin generation and
release [141–143]. Second, ammonium chloride–induced
metabolic acidosis in healthy adults is associated with a
1.5-fold increase in the b2-microglobulin mRNA expres-
sion in lymphocytes [143]. Third, in patients with CRF,
a strong inverse relationship has been demonstrated be-
tween serum total CO2 and b2-microglobulin levels [143].
Finally, using acetate instead of bicarbonate as a buffer
in dialysate is associated with a decrease in blood pH and
total CO2 and an increase in plasma b2-microglobulin
levels [143]. Thus, even though reduced renal excretion
of b2-microglobulin is the predominant mechanism for its
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accumulation in MHD patients, these data suggest that
metabolic acidosis may also play a role.
Hypertriglyceridemia
In a small, uncontrolled study of MHD patients, the
correction of metabolic acidosis was associated with
significant decrease in serum triglycerides, suggesting
that metabolic acidosis may contribute to hypertriglyc-
eridemia seen in MHD patients [139]. However, given
the limitations of study design, these data need to be con-
firmed before any definitive conclusions are made.
CONCLUSION
A large body of evidence suggests that uncorrected
metabolic acidosis is detrimental to the overall health and
specifically the nutritional status and bone disease among
MHD patients. Even though the relative contribution of
metabolic acidosis to the development of protein-energy
malnutrition or renal osteodystrophy remains to be de-
fined, the correction of metabolic acidosis among MHD
patients appears to be a desirable goal.
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